Table 2.
Demographics and IVF/ICSI treatment characteristics of the live-birth and the non-live-birth groups of fresh cycles.
| Live-birth group (n = 699) | Non-live-birth group (n = 534) | t | χ2 | p-value | |
|---|---|---|---|---|---|
| Age (y) | 36.90 ± 2.04 | 38.54 ± 2.79 | -11.949 | <0.001* | |
| Infertility duration (y) | 4.44 ± 3.90 | 4.43 ± 3.98 | 0.055 | 0.956 | |
| BMI (kg/m2) | 24.09 ± 3.08 | 23.91 ± 3.08 | 0.977 | 0.329 | |
| Basal FSH (IU/L) | 6.95 ± 2.08 | 7.44 ± 2.35 | -3.868 | <0.001* | |
| Basal LH (IU/L) | 5.14 ± 3.16 | 4.96 ± 3.30 | 0.962 | 0.336 | |
| LH/FSH | 0.78 ± 0.54 | 0.70 ± 0.56 | 2.461 | 0.014 | |
| Basal T (nmol/l) | 0.71 ± 0.42 | 0.64 ± 0.35 | 3.221 | 0.001 | |
| AFC | 16.00 ± 6.31 | 13.04 ± 5.23 | 8.779 | <0.001* | |
| AMH (pmol/l) | 26.08 ± 17.44 | 18.64 ± 13.87 | 7.188 | <0.001* | |
| Insulin resistance (%)1 | 82.12% (147/179) | 74.60% (94/126) | 2522 | 0.112 | |
| Starting Gn (IU) | 226.73 ± 58.04 | 66.41 ± 19.26 | -7.219 | <0.001* | |
| Gn duration (day) | 12.97 ± 2.14 | 13.11 ± 2.42 | -1.142 | 0.254 | |
| rLH supplementation (Y/N) (%) | 58.80% (411/699) | 51.50% (275/534) | 6.536 | 0.011* | |
| Number of oocytes retrieved | 13.53 ± 6.33 | 9.74 ± 5.27 | 11.189 | <0.001* | |
| Number of 2PN | 9.05 ± 4.85 | 5.50 ± 3.53 | 14.279 | <0.001* |
Values are expressed as percentage (%) or mean and standard deviation (SD). P-value < 0.05 (asterisk) was considered statistically significant. (IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; PCOS, Polycystic ovary syndrome; BMI, body mass index; LH, luteinizing hormone; FSH, follicle-stimulating hormone; T, testosterone; Gn, gonadotropin; rLH, recombinant luteinizing hormone).
1There were 520 patients in the live-birth group who had no insulin release test, and 408 patients in the non-live-birth group who had no insulin release test.
The result of the P value is shown in italics.